Brief: Sensorion Submits Clinical Trial Application For OTOF-GT

Sensorion SA

19/07/2023 06:32

July 19 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION SUBMITS CLINICAL TRIAL APPLICATION FOR OTOF-GT,
ITS
LEAD GENE THERAPY CANDIDATE, IN EUROPE
    * SUBMITTED A CLINICAL TRIAL APPLICATION (CTA) TO INITIATE A
PHASE
1/2 CLINICAL TRIAL OF OTOF-GT IN EUROPE (FRANCE, ITALY AND
GERMANY)
    * PHASE 1/2 CLINICAL TRIAL (AUDIOGENE) AIMS TO EVALUATE
SAFETY,
TOLERABILITY AND EFFICACY OF INTRA-COCHLEAR ADMINISTRATION OF
OTOF-GT
    * CTAS SUBMISSION FOLLOWS EXTENSIVE PRECLINICAL STUDIES
ASSESSING
SAFETY AND EFFICACY OF OTOF-GT AND SUCCESSFUL MANUFACTURING OF
GENE THERAPY DRUG PRODUCT FOR CLINICAL TRIAL
    * EVALUATION FOR TREATMENT OF OTOFERLIN GENE-MEDIATED
HEARING LOSS
IN PEDIATRIC PATIENTS AGED FROM 6 TO 31 MONTHS

Source text for Eikon:  ID:nBw6phm6ya 
Further company coverage:  ALSEN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))